Welcome to our dedicated page for RETINALGENIX TECHNOLOGIES news (Ticker: $RTGN), a resource for investors and traders seeking the latest updates and insights on RETINALGENIX TECHNOLOGIES stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RETINALGENIX TECHNOLOGIES's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RETINALGENIX TECHNOLOGIES's position in the market.
Rhea-AI Summary
RetinalGeniX Technologies Inc. (RTGN) has been granted a patent for a System And Method For Visualization Of Ocular Anatomy by the USPTO. The invention aims to detect ocular and systemic diseases early by visualizing eye anatomy and identifying changes in eye geography. It can help diagnose various conditions like cataracts, retinitis pigmentosa, Alzheimer's, Parkinson's, and other conformational diseases. The Company believes this patent will revolutionize disease detection and diagnosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.9%
Tags
-
Rhea-AI Summary
RetinalGeniX™ Technologies Inc. (RTGN) has contracted MEDsan, Inc. to provide diagnostic testing services for a study on personalized medical evaluations for patients with wet macular degeneration. The company has also started planning pharmaceutical clinical studies for treating dry Age-Related Macular Degeneration (AMD) and Alzheimer’s/dementia complex studies. Additionally, RetinalGeniX has filed two provisional patents related to these studies and formed an institutional review board to launch a 390-patient clinical study intended to validate the relative suitability of anti-VEGF ocular injection treatments for patient candidates with wet AMD. The company is also developing a high-resolution retinal home and remote monitoring system intended to offer 24/7 real-time alerts to both physicians and patients without requiring dilation of the pupil. The technology aims to prevent blindness through early detection and treatment of ocular diseases and detect initial physiological changes indicating possible future systemic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
RetinalGeniX Technologies Inc. (OTCQB: RTGN) announced the addition of Anatoly Dritschilo, M.D. to its Medical Advisory Board. Dr. Dritschilo, a renowned educator and translational scientist, will support the company's development of High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies. The company is also progressing in conducting pharmaceutical clinical studies for treating dry Age-Related Macular Degeneration (AMD) and developing plans for a future study of Alzheimer's/Dementia complex. RetinalGeniX has filed two provisional patents related to these studies and formed an institutional review board to launch a 390-patient clinical study intended to validate the relative suitability of anti-VEGF ocular injection treatments for patient candidates with wet AMD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
RetinalGeniX Technologies Inc. (RTGN) announced the addition of Dr. Dessislava Boneva to its Board of Directors. Dr. Boneva, an experienced surgeon, brings over 20 years of experience to the company. RetinalGeniX focuses on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
RetinalGeniX Technologies Inc. (RTGN) has hired Virender Ahluwalia as Interim Chief Financial Officer. The company focuses on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies to prevent blindness through early detection and treatment of ocular diseases. Mr. Ahluwalia brings over 15 years of finance and operations experience and is expected to contribute to the company's growth. RetinalGeniX is conducting pharmaceutical clinical studies for treating dry Age-Related Macular Degeneration (AMD) and Alzheimer's/Dementia complex, and has filed provisional patents related to these studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
RetinalGeniX™ Technologies, Inc. (RTGN) announced the addition of Stephen Tannenbaum to the Business Advisory Board. Tannenbaum, a seasoned professional in capital markets, will provide strategic business advice, consult on potential mergers and acquisitions, and the development of channels to acquire additional capital for the Company. This move is expected to further strengthen RetinalGeniX as it pursues its mission to revolutionize healthcare technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) announced the submission of two provisional patent applications for investigational therapeutic drug candidates RTG-2023 and RTG-2024. RTG-2023 targets dry age-related macular degeneration (AMD) and RTG-2024 is intended for the treatment of dementia, specifically Alzheimer’s syndrome. The company's novel approach includes high-resolution retinal imaging and pharmacogenetic mapping to be combined with the promise of these investigational drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
RetinalGeniX™ Technologies Inc. (RTGN) has partnered with Avania CRO to guide its FDA interactions for the development of RTG-2023 for dry age-related macular degeneration and RTG-2024 for Alzheimer’s syndrome dementia, along with the RetinalCam™ image visualization device. Avania is a unique Clinical Research Organization with expertise in ophthalmology, aligning closely with RetinalGeniX’s development plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
RetinalGeniX Technologies Inc. has announced the launch of an Institutional Review Board for research on its DNA/GPS program. The study aims to identify hematology biomarkers that may help personalize medical evaluations for patients undergoing treatments for wet macular degeneration. The company's goal is to determine if a patient with active exudative AMD will respond better to intravitreal aflibercept versus intravitreal bevacizumab. The study has the potential to reduce costs and improve the safety and efficacy of patient candidate selection for ocular injections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
RetinalGeniX Technologies Inc. releases video webinar on retinal screening medical device technology, combining genetic markers and high-resolution retinal imaging in disease treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
RETINALGENIX TECHNOLOGIES
OTC:RTGN
RTGN Rankings
RTGN Stock Data
62.25M
5.33M
68.9%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
Petaluma